Gate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
Altimmune Announces Leadership Transition: Vipin K. Garg To Exit, Jerry Durso Takes Over as CEO
Altimmune, Inc. (ALT), the peptide therapeutics specialist developing treatment solutions for liver and metabolic conditions, has announced a significant leadership shift. The company revealed that CEO Vipin K. Garg will be departing his position, effective January 1, 2026. This leadership change marks a transition as Jerry Durso, currently serving as Chairman of the Board, will expand his responsibilities to include the Chief Executive Officer role.
Background on New CEO Jerry Durso
Durso’s appointment to Altimmune’s Board came in February of this year, and he was elevated to Chairman in August. His healthcare industry credentials span decades, including a tenure as Chief Executive at Intercept Pharmaceuticals Inc. (ICPT), where he led the company’s operations in the liver disease treatment space. Prior to that, Durso accumulated more than 20 years of industry experience at pharmaceutical giant Sanofi SA (SNY, SAN.PA, SNYNF), building substantial expertise in the sector.
Market Reaction to Management Shift
The announcement triggered an immediate response in pre-market trading. Altimmune’s stock declined 4.75%, trading at $5.01 on the Nasdaq during the pre-market session. The market pullback reflects typical investor sentiment surrounding leadership transitions in biotech firms.
Disclaimer: The perspectives shared in this article represent independent analysis and do not necessarily reflect the official positions of Nasdaq, Inc.